Show simple item record

dc.contributor.authorDe Jager, R
dc.contributor.authorSiegenthaler, P
dc.contributor.authorCavalli, F
dc.contributor.authorKlepp, O
dc.contributor.authorBramwell, Vivien H C
dc.contributor.authorJoss, R
dc.contributor.authorAlberto, P
dc.contributor.authorvan Glabbeke, M
dc.contributor.authorRenard, J
dc.contributor.authorRozencweig, M
dc.contributor.authorHansen, H H
dc.date.accessioned2014-12-22T15:29:20Z
dc.date.available2014-12-22T15:29:20Z
dc.date.issued1983-02
dc.identifier.citationPhase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-Group. 1983, 19 (2):289-93 Eur J Cancer Clin Oncolen
dc.identifier.issn0277-5379
dc.identifier.pmid6687457
dc.identifier.urihttp://hdl.handle.net/10541/337545
dc.description.abstractA total of 239 patients with advanced solid tumors were treated in this phase II trial. Amsacrine was administered as a single i.v. dose of 120 mg/m2 repeated at 21-day intervals. The initial dose was reduced to 90 mg/m2 in the case of extensive prior therapy. Some antitumor activity was detected in head and neck cancer but the drug appears to lack significant efficacy in epidermoid lung cancer as well as in carcinoma of the breast, melanoma, renal cell cancer, colorectal cancer and non-seminomatous testicular cancer. Leukopenia was the major toxic effect encountered in this trial and was similar at 90 and 120 mg/m2.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer & clinical oncologyen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAminoacridines
dc.subject.meshAmsacrine
dc.subject.meshAntineoplastic Agents
dc.subject.meshBlood Cell Count
dc.subject.meshDrug Administration Schedule
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLeukopenia
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.titlePhase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-Group.en
dc.typeArticleen
dc.contributor.departmentInstitut Jules Bordet, Rue Heger-Bordet, 1, 1000 Brussels, Belgiumen
dc.identifier.journalEuropean Journal of Cancer & Clinical Oncologyen
html.description.abstractA total of 239 patients with advanced solid tumors were treated in this phase II trial. Amsacrine was administered as a single i.v. dose of 120 mg/m2 repeated at 21-day intervals. The initial dose was reduced to 90 mg/m2 in the case of extensive prior therapy. Some antitumor activity was detected in head and neck cancer but the drug appears to lack significant efficacy in epidermoid lung cancer as well as in carcinoma of the breast, melanoma, renal cell cancer, colorectal cancer and non-seminomatous testicular cancer. Leukopenia was the major toxic effect encountered in this trial and was similar at 90 and 120 mg/m2.


This item appears in the following Collection(s)

Show simple item record